Ontario Cancer Research Ethics Board
MaRS Centre, Suite 510 | 661 University Avenue
Toronto, Ontario | Canada M5G 0A3
416-673-6649 or 1-866-678-6427 ext. 6649 | www.ocreb.ca
Monthly Teleconference Summary
June 5, 2015 @ 9am
ATTENDEES
1.
2.
3.
Sites: 4.
5.
6.
7.
OCREB:
8. Sunnybrook Health Sciences Centre
 Odette Cancer Centre
9. Toronto East General
10. Trillium Health Partners - Credit Valley Hospital
11. UHN - Princess Margaret Cancer Centre
 Clinical Trial Support Unit
12. William Osler Health Centre
Aurora de Borja, Terry Liu, Janet Manzo, Safia Moosvi, Cindy Sandel, Richard Sugarman (Chair),
Alison van Nie, Kathie Zeman
REGRETS
13.
14.
15.
16.
Sites:
17.
18.
19.
20.
OCREB:
Hamilton Health Sciences (JCC)
Health Sciences North (Sudbury)
Lawson (London) - LRCP
Niagara Health System
The Ottawa Hospital – Cancer Program
Royal Victoria Regional Health Centre
Southlake Regional Health Centre
Cambridge Memorial
Grand River Hospital
Humber River Hospital
Kingston General Hospital
Lakeridge Health (Oshawa)
Mount Sinai Hospital
North York General Hospital
SickKids (Toronto)
21.
22.
23.
24.
25.
26.
27.
St. Joseph’s Healthcare (Hamilton)
St. Joseph’s Health Centre (Toronto)
St. Michael’s Hospital
Thunder Bay Regional Health Sciences Centre
Trillium Health Partners - Mississauga Hospital
Windsor Regional Hospital
Women’s College Hospital
Yooj Ko (VC), Mark Whissell (VC),
If you temporarily have to leave the teleconference, please hang up and dial in again when you are able to rejoin. Putting your phone on hold causes interference with all of the other lines.
If you no longer wish to receive the monthly teleconference agendas and minutes, please contact Alison van Nie
at alison.vannie@oicr.on.ca to be removed from the OCREB distribution list. NOTE. You will no longer receive
communication from OCREB, with the exception of relevant business communication, as applicable. You may
request to be reinstated in the distribution list at any time.
NOTEWORTHY ITEMS
A place for sharing new information, updates and other noteworthy items affecting the research community…
Regulatory/Guidance Updates:
Regulatory Issues of Interest:
1. The Research Clinic. http://ori.hhs.gov/TheResearchClinic
The Office of Research Integrity (ORI) and the Office for Human Research Protections (OHRP) present
The Research Clinic. The interactive training video educates clinical and social researchers on the
importance of appropriately protecting research subjects and avoiding research misconduct.
2. Quorum follow up to: the ResearchKit vs. FDA draft Guidance:
eConsent Mashup: FDA Guidance vs. ResearchKit
3. What can go wrong with informed consent documents? Plenty ... news from the FDA
 Lack of proper signatures and dates
 Non-English speakers signing English consent documents
Teleconference 2015-Jun-05
Page 1 of 17





Lack of signatures from legally authorized representatives
Forged signatures
Consent obtained from subjects who lacked the capacity to give consent
Inadequate disclosure of risks associated with a trial protocol
Consent forms used without REB approval
Newsworthy/items of interest:
1. International Clinical Trials Day
Below are news releases and links related to International Clinical Trials Day.
 New Products and Partnership Agreements Mark International Clinical Trials Day at HealthCareCAN
and the Network of Networks
 Clinical Trials at Canada’s Academic Health Centres
 What is the single greatest development that will help improve clinical trials? (Part One)
 What is the single greatest development that will help improve clinical trials? (Part Two)
2. Journal Article: Clinical trialist perspectives on the ethics of adaptive clinical trials: a mixed methods
analysis BMC Medical Ethics (2015) 16:27
Summary:
One prerequisite of conducting any clinical trial is the careful consideration of the ethics of the trial
procedures.
 Trial design impacts scientific ethics (it is unethical to conduct an invalid study),
o individual ethics (which patients are allowed to participate and what scientific and
experimental procedures are they exposed to) and
o collective ethics (the need to discover better treatments or treatments for untreatable
conditions to improve future patient outcomes).
The ethical aspects of fixed RCTs and ACTs differ.
RCTs favour collective ethics:
 The statistical focus of fixed RCTs, particularly those studies designed to change clinical
practice or lead to drug or device approval (phase III or confirmatory), is to test hypotheses
about treatment effect.

In such trials, the primary goal of a trial is to improve the treatment for the broader
community, with individuals within the trial only conferring benefit if they are randomly
allocated to the better treatment (if one is indeed found to be better).
 Through informed consent, potential research participants decide themselves whether to be in a
trial, or opt for conventional therapy.
ACTs favour individual ethics:
 ACTs have different ethical nuances than more traditional, fixed RCTs.
 In addition to the need for an informed decision whether to participate in the trial or choose
conventional therapy, there are other ethical considerations.
 For example, some adaptive design strategies increase the probability of receiving the more
effective treatment while maintaining the scientific rigour of the trial. This emphasizes
individual ethics because the objective is to treat as many patients effectively as is possible.
 The potential advantage over fixed RCTs is that more patients will be assigned to the
better-performing treatment arm(s), regardless of which arm(s) that turns out to be. This
introduces one example of a potentially favorable ethical outcome not present in a fixed
RCT.
 A more recent review focused on the potential ethical risks of such trial designs,
particularly highlighting the lack of equipoise that develops as the trial goes on and the
inherent injustice that later enrolling subjects will get better treatments than earlier enrolling
subjects.
 Clinical trials in the critically ill are particularly challenging. Interesting, a hypothetical clinical
trial scenario demonstrated greater participation when participants were offered a trial with
response adaptive randomization.
3. The Chronicle of Higher Education (from CAREB conference) U. of Minnesota Acknowledges Errors in a
Second Psychiatric-Research Case
Teleconference 2015-Jun-05
Page 2 of 17
4. NY Times article Company Creates Bioethics Panel on Trial Drugs Company Creates Bioethics Panel
on Trial Drugs
5. Do the dying have the right to experimental drugs?
NOTICES
Revised OCREB Main ICF (and harmonized consent) – v2015-June-01
Please note that the revised consent (developed and revised in tandem with the harmonized OCREB/NCIC ICF)
has been posted on the O2 website. The harmonized OCREB/NCIC Main ICF has not been posted (since NCIC
will submit the ICF to the provincial applicant using the approved template).
Note: The Memo for the Implementation of the OCREB NCIC ICF template (v2015-June-01), has been posted
under MEMOS on the O2 webpage, and includes the additional language which must be added to the NCIC
template when it is submitted (by the PA).
Use of OCREB Main ICF Template
Please note that the OCREB consent templates must be used and should be provided to the Sponsor or CRO
as applicable for the submissions; initial submissions that do not include consents using the OCREB templates
will be rejected.
Revised OCREB Consent Update – v2015-May-26
Please note that the Informed Consent Update Form has been revised. (minor changes to instructional text,
etc.).
Revised SOP 701
The SOP was revised (5.1.9) to indicate that the Pregnant Partner ICF must be submitted only when/if there is a
requirement for its implementation.
O2 Training
Hands-on new user, refresher training and advanced training sessions can be made available via webcast for
provincial or centre applications. On-site training (i.e., at the centre) can be arranged if there are enough
attendees. For those in the GTA, training at the OCREB office also can be arranged. The next training sessions
are scheduled for June 11th, 10-2pm.
Please contact Kathie Zeman or Aurora de Borja to arrange O2 training.
REMINDERS
Implementing the approved Provincial ICFs
Please remember to use the approved ICF templates (and other participant materials) for the study as posted on
the O2 workspace to ensure that the centre consent is the currently approved provincial consent (with applicable
center-specific, pre-approved changes). Please refrain from revising the formatting other than to adjust for the
addition of the letterhead to ensure that page breaks are in the appropriate place (e.g., a section header alone is
not on one page and all of the content of the section on another). Formatting does not include changing the font
size, type or case, wording changes or the correction of grammar errors.
Centre CR submissions
Please provide the most recent version of the ICFs in word format (i.e., not pdf) and all Consent Update ICF
Forms at the time of the submission. The consents (required in word format) must be verified with the
provincially approved versions.
IB and ICF changes
Please ensure that if there are changes to the risks, as part of the IB revisions, that a consent update is
included, if applicable, and a revised main consent if enrolment is continuing.
Teleconference 2015-Jun-05
Page 3 of 17
Review of ICF and sponsor approval prior to implementation
Please ensure that your consents are reviewed by the sponsor prior to submission.
Sponsor correspondence
Please remember to include all related sponsor correspondence with reportable events/amendments as
applicable.
OCREB MANDATE
Occasionally, OCREB is asked to accept multi-centre cancer research that does not fit our mandate. While we
recognize that there is very important non-clinical trial research that could benefit from a centralized ethics
review, we do not have the expertise, processes and resources to accept research that falls outside OCREB’s
mandate. For the purposes of its current mandate, "multi-centre" is defined as more than one participating
Ontario centre, and "clinical trial" is defined as any research that prospectively assigns human participants to
one or more health-related interventions to evaluate the effects on health outcomes. Interventions are restricted
to drugs and other biological products, surgical procedures, radiological procedures and devices.
Implementation at the Centre level of the OCREB ICF provincially approved ICF
Please remember to retain the version date on the provincially approved document when adding centre-specific
(pre-approved) information.
OCREB Membership Changes
The OCREB membership roster was last updated on June 1, 2015. The current and archived membership lists
can be accessed from https://ocrebonline.ca under “Membership”.
Project Submission Summary List
The list of studies with OCREB (project submission summary spreadsheet) is available on the O2 Home page
https://ocrebonline.ca. The current version posted is from May 29, 2015.
OCREB ONLINE (O2)
Key Recent Enhancements
See also the “What’s New” section of O2 Home - https://ocrebonline.ca
A patch was applied to the system on June 4, 2015. The changes do not affect end users.
Outstanding issues (logged but not yet resolved):


Guidance text feature for application forms and workspaces;
Archiving for 25 years so system can be used as ethics study files.
STUDY SUBMISSION STATUS
For a list of all studies with OCREB, see the Project Submission spreadsheet at https://ocrebonline.ca
New studies submitted for the June meeting:
15-039
Kathie
UHN
Carbo-Pem-MEK162NSCLC
Leighl, Natasha
UHN
Maggie Sawczak
15-040
Cindy
Incyte
INCB 18424-267
Chen, Eric
UHN
Bonnie Kwan
15-041
Aurora
OCOG
OCOG-2015-ATOM
Levine, Mark
OCOG
Beverly Pond
Teleconference 2015-Jun-05
Page 4 of 17
15-042
Cindy
AZ
D5165C00001
Goss, Glenwood
15-043
Cindy
OCOG
15-044
Kathie
15-045
TOH
OCOG-2013-PETMUSE
Levine, Mark
NCIC
LY.17
Kuruvilla, John
UHN
Nanthini Tharahan
Aurora
NCIC
MA.32D
Bedard, Phillippe
UHN
Anna Malik
15-046
Aurora
Pfizer
A5481034
TOH
Yuhui Xu
15-047
Aurora
PMHC
PHL-095
Verma, Shailendra
Krzyzanowska,
Monika
UHN
15-048
Kathie
COG
AHOD1331
Alexander, Sarah
HSC
Bonnie Kwan
Nivetha
Ramachandran
15-049
Kathie
COG
AHOD1221
Alexander, Sarah
HSC
Catherine Deveault
15-050
Cindy
NCIC
SRC.7
Gupta, Abha
UHN
Nanthini Tharahan
15-051
Aurora
UHN
ACDC-RP
Fleshner, Neil
UHN
Miran Kenk
15-052
Aurora
IIS
TOPCOP
Alibhai, Shabbir
UHN
Henriette Breunis
15-053
Aurora
UHN
LIGAND
Fleshner, Neil
UHN
Miran Kenk
15-054
Cindy
AZ
D419AC00001
Robinson, Andrew
KGH
Carrie Lindsaay
OCOG
Amy Henderson
Beverly Pond
Studies in Pre Submission:
Sanofi
LPS14022
Winquist, Eric
LHSC
Mary Beth Husson
Exelixis
XL184–401
Krzyzanowska, Monika
UHN
Amirah Shahin
UHN
IMRT Phase III RCT-31
Chung, Peter
UHN
Shawde Harris
COG
AEWS1221
Gupta, Abha
HSC
Mandie Mio
Other Potential Studies:
CONTINUING REVIEW APPLICATIONS DUE FOR THE JULY MEETING –
see next section
Be sure to keep track of the expiry dates of your studies. The system sends courtesy reminders 49 days, 15
days and 1 day prior to the expiry date.
There are approximately 49 studies involving 143 centre applications (approximately 192 continuing review
applications) due by the June 25th deadline for the July 10th, 2015 OCREB Meeting, (i.e., expiring July 10th to
August 13th 2015, inclusive), unless a study closure has been or will be submitted.
Next OCREB teleconference: July 3, 2015 @9am
Teleconference 2015-Jun-05
Page 5 of 17
CONTINUING REVIEW APPLICATIONS DUE FOR THE JULY MEETING
OCREB
#
REC
Sponsor
06-041
Cindy Sandel
06-041
Cindy Sandel
06-041
Cindy Sandel
06-041
Cindy Sandel
06-046
Cindy Sandel
06-046
Cindy Sandel
06-046
Cindy Sandel
06-046
Cindy Sandel
07-053
Cindy Sandel
07-053
Cindy Sandel
07-053
Cindy Sandel
07-053
Cindy Sandel
07-053
Cindy Sandel
Ontario Clinical
Oncology
Group(OCOG)
Ontario Clinical
Oncology
Group(OCOG)
Ontario Clinical
Oncology
Group(OCOG)
Ontario Clinical
Oncology
Group(OCOG)
NCIC Clinical
Trials Group
(NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical
Trials Group
(NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
08-038
Cindy Sandel
GlaxoSmithKline
08-038
08-041
Cindy Sandel
Aurora de
Borja
09-040
Cindy Sandel
Teleconference 2014-Jan-03
Protocol #
PI
Centre
Centre
Contact
Application
Type
Expiry
Date
06-041
Lukka,
Himanshu R.
Hamilton Health Sciences
Yvonne Kinrade
Provincial
8/8/2015
06-041
Lukka,
Himanshu R.
Hamilton Health Sciences
Yvonne Kinrade
Centre
8/8/2015
06-041
Bauman, Glenn
S.
Lawson Health Research
Institute(London)
Mary Beth
Husson
Centre
8/8/2015
06-041
Malone, Shawn
The Ottawa Hospital
Lisa Turriff
Centre
8/8/2015
06-046
Bin, James
Toronto East General
Hospital
Christine
Stewart
Provincial
8/8/2015
06-046
Bin, James
Amir (UHN),
Eitan
Chouinard,
Edmond E.
Toronto East General Hospital
UHN-Princess Margaret Cancer
Centre
Christine Stewart
Centre
8/8/2015
Annie Le
Centre
8/8/2015
Cambridge Memorial Hospital
Stephanie Evans
Centre
8/8/2015
UHN-Princess Margaret
Cancer Centre
UHN-Princess Margaret Cancer
Centre
Thunder Bay Regional Health
Sciences Centre
Anna Malik
Provincial
8/8/2015
Anna Malik
Centre
8/8/2015
Carol Pelletier
Centre
8/8/2015
The Ottawa Hospital
Lawson Health Research
Institute(London)
Amy Henderson
Mary Beth
Husson
Centre
8/8/2015
Centre
8/8/2015
08-038
Leighl, Natasha
B.
Leighl, Natasha
B.
Dueck, DorieAnna C.
Goss, Glenwood
D.
Dingle, Brian
Henry
Reaume, Martin
Neil
Femina Kanji
Provincial
8/7/2015
GlaxoSmithKline
08-038
Knox, Jennifer J.
Simon Lam
Centre
8/7/2015
Eli Lilly Canada
Ontario Clinical
Oncology
Group(OCOG)
08-041
Brade, Anthony
The Ottawa Hospital
UHN-Princess Margaret Cancer
Centre
UHN-Princess Margaret
Cancer Centre
Shawde Harris
Provincial
7/24/2015
09-040
Elit, Laurie
Hamilton Health Sciences
Yvonne Kinrade
Provincial
8/8/2015
06-046
06-046
07-053
07-053
07-053
07-053
07-053
Page 6 of 17
OCREB
#
REC
09-040
Cindy Sandel
09-040
Cindy Sandel
09-040
Cindy Sandel
09-040
Cindy Sandel
09-040
Cindy Sandel
09-040
Cindy Sandel
09-042
Kathie
Zeman
09-044
Kathie
Zeman
09-044
Kathie Zeman
09-044
Kathie Zeman
09-044
Kathie Zeman
09-047
09-047
10-061
10-061
10-067
10-067
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Teleconference 2014-Jan-03
Sponsor
Ontario Clinical
Oncology
Group(OCOG)
Ontario Clinical
Oncology
Group(OCOG)
Ontario Clinical
Oncology
Group(OCOG)
Ontario Clinical
Oncology
Group(OCOG)
Ontario Clinical
Oncology
Group(OCOG)
Ontario Clinical
Oncology
Group(OCOG)
NCIC Clinical
Trials Group
(NCIC CTG)
NCIC Clinical
Trials Group
(NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical
Trials Group
(NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
Canadian Urologic
Oncology Group
Canadian Urologic
Oncology Group
Boehringer
Ingelheim Canada
Ltd.
Boehringer
Ingelheim Canada
Protocol #
PI
Centre
Centre
Contact
Application
Type
Expiry
Date
09-040
Barbera, Lisa
Sunnybrook Health Sciences
Centre
Jessica Marer
Centre
8/8/2015
09-040
D'Souza, David
P.
Lawson Health Research
Institute(London)
Mary Beth
Husson
Centre
8/8/2015
09-040
Fyles, Anthony
W.
UHN-Princess Margaret Cancer
Centre
Shawde Harris
Centre
8/8/2015
09-040
Samant, Rajiv S
The Ottawa Hospital
Femina Kanji
Centre
8/8/2015
09-040
Elit, Laurie
Hamilton Health Sciences
Yvonne Kinrade
Centre
8/8/2015
09-040
Anthes,
Margaret L.
Thunder Bay Regional Health
Sciences Centre
Carol Pelletier
Centre
8/8/2015
09-042
Leighl, Natasha
B.
UHN-Princess Margaret
Cancer Centre
Tuhina Paul - St.
Hilaire
Provincial
8/7/2015
UHN-Princess Margaret
Cancer Centre
UHN-Princess Margaret Cancer
Centre
Kathryn Sabate
Provincial
8/8/2015
Kathryn Sabate
Centre
8/8/2015
Hamilton Health Sciences
Lawson Health Research
Institute(London)
Yvonne Kinrade
Mary Beth
Husson
Centre
8/8/2015
09-044
Mason, Warren
P.
Mason, Warren
P.
Greenspoon,
Jeffrey
Macdonald,
David
Centre
8/8/2015
09-047
Ellis, Peter
Yvonne Kinrade
Provincial
7/25/2015
09-047
Liu, Geoffrey
Nishreen Leila
Centre
7/25/2015
10-061
Jewett, Michael
Laura Legere
Provincial
8/8/2015
10-061
Jewett, Michael
Hamilton Health Sciences
UHN-Princess Margaret Cancer
Centre
UHN-Princess Margaret
Cancer Centre
UHN-Princess Margaret Cancer
Centre
Asma Shaikh
Centre
8/8/2015
Hamilton Health Sciences
Yvonne Kinrade
Provincial
7/25/2015
Hamilton Health Sciences
Yvonne Kinrade
Centre
7/25/2015
09-044
09-044
09-044
10-067
10-067
Hirte, Holger
(Hal) W.
Hirte, Holger
(Hal) W.
Page 7 of 17
OCREB
#
REC
Sponsor
Protocol #
PI
Centre
Centre
Contact
Application
Type
Expiry
Date
Ltd.
10-067
10-067
10-068
10-068
10-069
10-069
10-069
10-069
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Kathie
Zeman
Boehringer
Ingelheim Canada
Ltd.
Boehringer
Ingelheim Canada
Ltd.
10-067
Welch, Stephen
10-067
GlaxoSmithKline
10-068
GlaxoSmithKline
Amgen Canada
Inc.
10-068
Oza, Amit M.
McCarron,
Bonnie I.
McCarron,
Bonnie I.
10-069
Oza, Amit M.
Amgen Canada Inc.
10-069
Covens, Allan L.
Amgen Canada Inc.
10-069
Welch, Stephen
Amgen Canada Inc.
Duke Cancer
Institute
Duke Cancer
Institute
10-069
Medivation, Inc
10-073
10-073
Kathie Zeman
Kathie
Zeman
10-073
Kathie Zeman
Medivation, Inc
10-073
Oza, Amit M.
MacKenzie,
Mary J.
MacKenzie,
Mary J.
Joshua,
Anthony
Winquist, Eric
W.
10-073
Kathie Zeman
Medivation, Inc
10-073
Joshua, Anthony
10-073
Kathie Zeman
Medivation, Inc
10-073
10-073
Kathie Zeman
Medivation, Inc
10-073
Klotz, Laurence
Canil, Christina
Maria
10-073
Kathie Zeman
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Medivation, Inc
10-073
GlaxoSmithKline
10-074
GlaxoSmithKline
10-074
GlaxoSmithKline
10-074
10-071
10-071
10-074
10-074
10-074
Teleconference 2014-Jan-03
10-071
10-071
Mukherjee, Som
Bjarnason,
Georg A.
Bjarnason,
Georg A.
Winquist, Eric
W.
Lawson Health Research
Institute(London)
Mary Beth
Husson
Centre
7/25/2015
UHN-Princess Margaret Cancer
Centre
Riddhi Gehi
Centre
7/25/2015
Grand River Hospital
Carol Ballantyne
Provincial
8/8/2015
Grand River Hospital
UHN-Princess Margaret
Cancer Centre
Sunnybrook Health Sciences
Centre
Lawson Health Research
Institute(London)
UHN-Princess Margaret Cancer
Centre
Lawson Health Research
Institute(London)
Lawson Health Research
Institute(London)
UHN-Princess Margaret
Cancer Centre
Lawson Health Research
Institute(London)
UHN-Princess Margaret Cancer
Centre
Sunnybrook Health Sciences
Centre
Carol Ballantyne
Centre
8/8/2015
Monika Schmuck
Provincial
8/8/2015
Jessica Marer
Mary Beth
Husson
Centre
8/8/2015
Centre
8/8/2015
Monika Schmuck
Mary Beth
Husson
Mary Beth
Husson
Centre
8/8/2015
Provincial
8/8/2015
Centre
8/8/2015
Grace Garcia
Mary Beth
Husson
Provincial
8/8/2015
Centre
8/8/2015
Grace Garcia
Marlene
Kebabdjian
Centre
8/8/2015
Centre
8/8/2015
The Ottawa Hospital
Lisa Turriff
Centre
8/8/2015
Hamilton Health Sciences
Sunnybrook Health Sciences
Centre
Sunnybrook Health Sciences
Centre
Lawson Health Research
Institute(London)
Yvonne Kinrade
Centre
8/8/2015
Jennifer Woo
Provincial
8/1/2015
Jennifer Woo
Mary Beth
Husson
Centre
8/1/2015
Centre
8/1/2015
Page 8 of 17
OCREB
#
REC
10-074
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
10-076
Aurora de
Borja
10-077
Aurora de
Borja
10-077
Aurora de
Borja
10-077
Aurora de
Borja
10-077
Aurora de
Borja
10-077
Aurora de
Borja
10-074
10-074
10-074
Teleconference 2014-Jan-03
Sponsor
Protocol #
PI
Centre
Centre
Contact
Application
Type
Expiry
Date
UHN-Princess Margaret Cancer
Centre
Asma Shaikh
Centre
8/1/2015
Lakeridge Health
Edeliza Mendoza
Centre
8/1/2015
Hamilton Health Sciences
Yvonne Kinrade
Centre
8/1/2015
The Ottawa Hospital
Lisa Turriff
Centre
8/1/2015
Mason, Warren
P.
UHN-Princess Margaret
Cancer Centre
Monique
Cardoza
Provincial
7/25/2015
10-077
Elser (UHN),
Christine
Mount Sinai Hospital
Claudia
Thiruchelvam
Provincial
8/8/2015
10-077
Elser (UHN),
Christine
UHN-Princess Margaret Cancer
Centre
Claudia
Thiruchelvam
Centre
8/8/2015
10-077
Hamm, Caroline
Windsor Regional Hospital
Krista Naccarato
Centre
8/8/2015
10-077
Potvin, Kylea R.
Lawson Health Research
Institute(London)
Mary Beth
Husson
Centre
8/8/2015
10-077
Haq, Rashida
St. Michael's Hospital
Aziz Jiwajee
Centre
8/8/2015
GlaxoSmithKline
10-074
GlaxoSmithKline
10-074
GlaxoSmithKline
10-074
GlaxoSmithKline
NCIC Clinical
Trials Group
(NCIC CTG)
Mount Sinai
Hospital’s The
Hold’eEm for Life
Translating
Discoveries in to
Breast Cancer
Cures
Mount Sinai
Hospital’s The
Hold’eEm for Life
Translating
Discoveries in to
Breast Cancer
Cures
Mount Sinai
Hospital’s The
Hold’eEm for Life
Translating
Discoveries in to
Breast Cancer
Cures
Mount Sinai
Hospital’s The
Hold’eEm for Life
Translating
Discoveries in to
Breast Cancer
Cures
Mount Sinai
Hospital’s The
Hold’eEm for Life
Translating
Discoveries in to
Breast Cancer
10-074
Knox, Jennifer J.
Zalewski, Pawel
G.
Kapoor(HHS),
Anil
Reaume, Martin
Neil
10-076
Page 9 of 17
OCREB
#
REC
Sponsor
Protocol #
PI
Centre
Centre
Contact
Application
Type
Expiry
Date
Cures
10-077
Aurora de
Borja
10-078
Cindy Sandel
10-078
Cindy Sandel
10-078
Cindy Sandel
10-078
Cindy Sandel
10-078
11-021
Cindy Sandel
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Kathie
Zeman
11-021
Kathie Zeman
11-021
Kathie Zeman
Aurora de
Borja
10-082
10-082
10-087
10-087
10-087
11-030
Teleconference 2014-Jan-03
Mount Sinai
Hospital’s The
Hold’eEm for Life
Translating
Discoveries in to
Breast Cancer
Cures
Ontario Institute
for Cancer
Research(OICR)
Ontario Institute for
Cancer
Research(OICR)
Ontario Institute for
Cancer
Research(OICR)
Ontario Institute for
Cancer
Research(OICR)
Ontario Institute for
Cancer
Research(OICR)
10-077
Goodwin (MSH),
Pamela
Mount Sinai Hospital
Olivera Jugovic
Centre
8/8/2015
10-078
Siu, Lillian LaiYun
UHN-Princess Margaret
Cancer Centre
Riddhi Gehi
Provincial
8/7/2015
10-078
Winquist, Eric
W.
Lawson Health Research
Institute(London)
Mary Beth
Husson
Centre
8/7/2015
10-078
Siu, Lillian LaiYun
UHN-Princess Margaret Cancer
Centre
Prachi Mohite
Centre
8/7/2015
10-078
Dueck, DorieAnna C.
Thunder Bay Regional Health
Sciences Centre
Carol Pelletier
Centre
8/7/2015
10-078
Goss, Glenwood
D.
The Ottawa Hospital
Centre
8/7/2015
GlaxoSmithKline
10-082
Chang, Jose
The Ottawa Hospital
Yuhui Xu
Edeliza
Mendoza
Provincial
7/31/2015
GlaxoSmithKline
10-082
Chang, Jose
Edeliza Mendoza
Centre
7/31/2015
GlaxoSmithKline
10-087
Hogg, David
Hamed Moazami
Provincial
8/8/2015
GlaxoSmithKline
10-087
Hamed Moazami
Centre
8/8/2015
GlaxoSmithKline
ImClone Systems
LLC
ImClone Systems
LLC
ImClone Systems
LLC
London Regional
Cancer Program
10-087
Carolyn Lim
Mary Beth
Husson
Mary Beth
Husson
Centre
8/8/2015
Provincial
8/1/2015
Centre
8/1/2015
11-021
Hogg, David
Petrella, Teresa
Marie
Winquist, Eric
W.
Winquist, Eric
W.
Sridhar (UHN),
Srikala S.
8/1/2015
Palma, David
Simon Lam
Mary Beth
Husson
Centre
11-030
Lakeridge Health
UHN-Princess Margaret
Cancer Centre
UHN-Princess Margaret Cancer
Centre
Sunnybrook Health Sciences
Centre
Lawson Health Research
Institute(London)
Lawson Health Research
Institute(London)
UHN-Princess Margaret Cancer
Centre
Lawson Health Research
Institute(London)
Provincial
8/8/2015
11-021
11-021
Page 10 of 17
OCREB
#
REC
11-030
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
11-038
Aurora de
Borja
11-030
11-030
11-030
11-039
Aurora de
Borja
Kathie
Zeman
11-039
11-038
Sponsor
London Regional
Cancer Program
London Regional
Cancer Program
London Regional
Cancer Program
London Regional
Cancer Program
Hoffmann-La
Roche Limited
(Canada)
Hoffmann-La
Roche Limited
(Canada)
Protocol #
11-030
11-030
11-030
PI
Palma, David
Swaminath,
Anand
11-030
Pearce, Andrew
Pantarotto,
Jason
11-038
Roitman, Daryl
S.
11-038
Roitman, Daryl
S.
Jonker, Derek
J.
Centre
Centre
Contact
Application
Type
Expiry
Date
Lawson Health Research
Institute(London)
Mary Beth
Husson
Centre
8/8/2015
Hamilton Health Sciences
Health Sciences North (Horizon
Santé-Nord)
Yvonne Kinrade
Centre
8/8/2015
Cathy Simeoni
Centre
8/8/2015
The Ottawa Hospital
Amy Henderson
Centre
8/8/2015
North York General Hospital
Anne Abraham
Provincial
8/8/2015
North York General Hospital
Jessica Zhang
Centre
8/8/2015
The Ottawa Hospital
Julie Wells
Provincial
8/1/2015
The Ottawa Hospital
UHN-Princess Margaret
Cancer Centre
UHN-Princess Margaret Cancer
Centre
Lawson Health Research
Institute(London)
Julie Wells
Gayathri
Baranage
Gayathri
Baranage
Mary Beth
Husson
Centre
8/1/2015
Provincial
8/8/2015
Centre
8/8/2015
Centre
8/8/2015
Amy Henderson
Mary Beth
Husson
Provincial
7/11/2015
Centre
7/11/2015
Jennerex Inc
11-039
Kathie Zeman
Jennerex Inc
11-039
11-041
Cindy Sandel
Eisai Inc.
11-041
11-041
Cindy Sandel
Eisai Inc.
11-041
11-041
Cindy Sandel
11-041
12-028
Kathie
Zeman
12-028
Jonker, Derek
J.
12-028
Kathie Zeman
12-028
Welch, Stephen
The Ottawa Hospital
Lawson Health Research
Institute(London)
12-028
Kathie Zeman
12-028
Jonker, Derek J.
The Ottawa Hospital
Amy Henderson
Centre
7/11/2015
12-028
Kathie Zeman
12-028
Goffin, John R.
Hamilton Health Sciences
Yvonne Kinrade
Centre
7/11/2015
12-028
Kathie Zeman
12-028
7/11/2015
Susan Namubiru
Centre
7/11/2015
12-028
Kathie Zeman
Aurora de
Borja
Kingston General Hospital
UHN-Princess Margaret Cancer
Centre
Sunnybrook Health Sciences
Centre
Centre
Kathie Zeman
7/11/2015
12-029
Adam Lam
Donna
Clinansmith
Centre
NRG Oncology
Tomiak, Anna T.
Chen, Eric
(Xueyu)
Ko, Yoo-Joung
(Yooj)
Hirmiz, Khalid
J.
Kristina Kulik
12-028
Eisai Inc.
NCIC Clinical
Trials Group
(NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
Jonker, Derek J.
Krzyzanowska,
Monika
Krzyzanowska,
Monika
Winquist, Eric
W.
Provincial
7/11/2015
12-029
Teleconference 2014-Jan-03
12-028
12-028
Windsor Regional Hospital
Page 11 of 17
OCREB
#
REC
12-029
Aurora de
Borja
Aurora de
Borja
12-030
Kathie
Zeman
12-030
Kathie Zeman
12-030
12-033
Kathie Zeman
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
12-035
Kathie
Zeman
12-035
Kathie Zeman
12-035
Kathie Zeman
12-035
Kathie Zeman
12-036
Cindy Sandel
12-036
Cindy Sandel
12-036
Cindy Sandel
12-029
12-033
12-033
12-033
12-033
12-033
Teleconference 2014-Jan-03
Sponsor
Protocol #
PI
Centre
Centre
Contact
Application
Type
Expiry
Date
Windsor Regional Hospital
Donna
Clinansmith
Centre
7/11/2015
Grand River Hospital
Carol Ballantyne
Centre
7/11/2015
Song, Xinni
UHN-Princess Margaret
Cancer Centre
Lisa Turriff
Provincial
7/11/2015
Petrella, Teresa
Marie
Sunnybrook Health Sciences
Centre
Carolyn Lim
Centre
7/11/2015
The Ottawa Hospital
Lisa Turriff
Centre
7/11/2015
Hamilton Health Sciences
Yvonne Kinrade
Provincial
7/11/2015
Hamilton Health Sciences
Lawson Health Research
Institute(London)
Sunnybrook Health Sciences
Centre
Yvonne Kinrade
Mary Beth
Husson
Centre
7/11/2015
Centre
7/11/2015
Jennifer Woo
Centre
7/11/2015
The Ottawa Hospital
Lisa Turriff
Centre
7/11/2015
12-033
Song, Xinni
Hotte,
Sébastien J.
Hotte, Sébastien
J.
Winquist, Eric
W.
Emmenegger,
Urban
Canil, Christina
Maria
Zalewski, Pawel
G.
Lakeridge Health
Edeliza Mendoza
Centre
7/11/2015
12-035
Dent, Susan F.
The Ottawa Hospital
Amy Henderson
Provincial
8/8/2015
12-035
Mates, Mihaela
Kingston General Hospital
Carrie Lindsay
Centre
8/8/2015
12-035
The Ottawa Hospital
Amy Henderson
Centre
8/8/2015
12-035
Dent, Susan F.
Dhesy-Thind,
Sukhbinder K.
Hamilton Health Sciences
Yvonne Kinrade
Centre
8/8/2015
12-036
Luk, Cynthia
Southlake Regional Health
Centre
Priyanka
Khandelwal
Provincial
8/7/2015
12-036
Kuruvilla, John
UHN-Princess Margaret Cancer
Centre
Nirosha
Srimathan
Centre
8/7/2015
12-036
Luk, Cynthia
Southlake Regional Health
Centre
Priyanka
Khandelwal
Centre
8/7/2015
NRG Oncology
12-029
NRG Oncology
Hoffmann-La
Roche Limited
(Canada)
Hoffmann-La
Roche Limited
(Canada)
Hoffmann-La
Roche Limited
(Canada)
Oncogenex
Technologies
Oncogenex
Technologies
Oncogenex
Technologies
Oncogenex
Technologies
Oncogenex
Technologies
Oncogenex
Technologies
NCIC Clinical
Trials Group
(NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
Hoffmann-La
Roche Limited
(Canada)
Hoffmann-La
Roche Limited
(Canada)
Hoffmann-La
Roche Limited
(Canada)
12-029
Hirmiz, Khalid J.
Gopaul,
Darindra
12-030
12-030
12-030
12-033
12-033
12-033
12-033
12-033
Page 12 of 17
OCREB
#
REC
12-036
Cindy Sandel
12-036
Cindy Sandel
12-036
Cindy Sandel
12-036
Cindy Sandel
12-036
Cindy Sandel
12-037
Kathie
Zeman
12-037
Kathie Zeman
12-037
Kathie Zeman
12-037
Kathie Zeman
12-037
Kathie Zeman
12-037
Kathie Zeman
12-037
Kathie Zeman
12-037
Kathie Zeman
12-037
Kathie Zeman
12-040
Kathie
Zeman
12-040
Kathie Zeman
12-040
Kathie Zeman
12-040
Kathie Zeman
Teleconference 2014-Jan-03
Sponsor
Hoffmann-La
Roche Limited
(Canada)
Hoffmann-La
Roche Limited
(Canada)
Hoffmann-La
Roche Limited
(Canada)
Hoffmann-La
Roche Limited
(Canada)
Hoffmann-La
Roche Limited
(Canada)
NCIC Clinical
Trials Group
(NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical
Trials Group
(NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
Protocol #
PI
Centre
Centre
Contact
Application
Type
Expiry
Date
12-036
Disperati,
Patricia
Toronto East General Hospital
Christine Stewart
Centre
8/7/2015
12-036
Kanjeekal, Sindu
Mary
Windsor Regional Hospital
Donna
Clinansmith
Centre
8/7/2015
12-036
MacEachern,
Janet A.
Grand River Hospital
Carol Ballantyne
Centre
8/7/2015
12-036
Nay , Derek
Royal Victoria Regional Health
Centre
Christine Di
Marco
Centre
8/7/2015
12-036
Kim, Christie
William Osler Health Centre
Mary Spiteri
Centre
8/7/2015
12-037
Kingston General Hospital
Kristina Kulik
Provincial
8/8/2015
The Ottawa Hospital
Amy Henderson
Centre
8/8/2015
Hamilton Health Sciences
Yvonne Kinrade
Centre
8/8/2015
12-037
Biagi, James
Cripps, Christine
(Mary)
McWhirter,
Elaine
Findlay, Brian
Peter
8/8/2015
Pressnail, Bryn
Linda Illes
Christine Di
Marco
Centre
12-037
Niagara Health System
Royal Victoria Regional Health
Centre
Centre
8/8/2015
12-037
Biagi, James
8/8/2015
Welch, Stephen
Kristina Kulik
Mary Beth
Husson
Centre
12-037
Kingston General Hospital
Lawson Health Research
Institute(London)
Centre
8/8/2015
12-037
Cano, Pablo O.
Sue Arkilander
Centre
8/8/2015
12-037
Wei, Alice C.C.
Anna Malik
Centre
8/8/2015
The Ottawa Hospital
Amy Henderson
Provincial
8/8/2015
Kingston General Hospital
Lawson Health Research
Institute(London)
UHN-Princess Margaret Cancer
Centre
Carrie Lindsay
Mary Beth
Husson
Centre
8/8/2015
Centre
8/8/2015
Nimisha Dave
Centre
8/8/2015
12-037
12-037
12-040
12-040
12-040
12-040
Nicholas, Garth
A.
Gregg, Richard
W.
Kuruvilla, Sara
Shepherd,
Frances A.
Health Sciences North (Horizon
Santé-Nord)
UHN-Princess Margaret Cancer
Centre
Page 13 of 17
OCREB
#
REC
12-040
Kathie Zeman
12-040
Kathie Zeman
12-040
Kathie Zeman
12-041
Cindy Sandel
12-041
Cindy Sandel
12-041
Cindy Sandel
12-041
Cindy Sandel
12-041
Cindy Sandel
Kathie
Zeman
13-020
13-020
13-042
Kathie Zeman
Kathie
Zeman
13-042
Kathie Zeman
13-042
Kathie Zeman
13-042
Kathie Zeman
13-044
Kathie
Zeman
13-044
Kathie Zeman
Teleconference 2014-Jan-03
Sponsor
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
Princess Margaret
Hospital
Consortium
(PMHC)
Princess Margaret
Hospital
Consortium
(PMHC)
Princess Margaret
Hospital
Consortium
(PMHC)
Princess Margaret
Hospital
Consortium
(PMHC)
Princess Margaret
Hospital
Consortium
(PMHC)
Protocol #
PI
Centre
Centre
Contact
Application
Type
Expiry
Date
12-040
Wierzbicki, Rafal
F.
Nicholas, Garth
A.
12-040
Goffin, John R.
Hamilton Health Sciences
Yvonne Kinrade
Centre
8/8/2015
12-041
Oza, Amit M.
UHN-Princess Margaret
Cancer Centre
Smitha Udagani
Provincial
8/8/2015
12-041
Welch, Stephen
Lawson Health Research
Institute(London)
Mary Beth
Husson
Centre
8/8/2015
12-041
Weberpals,
Johanne
The Ottawa Hospital
Lisa Turriff
Centre
8/8/2015
12-041
Oza, Amit M.
UHN-Princess Margaret Cancer
Centre
Smitha Udagani
Centre
8/8/2015
Hamilton Health Sciences
UHN-Princess Margaret
Cancer Centre
UHN-Princess Margaret Cancer
Centre
UHN-Princess Margaret
Cancer Centre
Lawson Health Research
Institute(London)
Yvonne Kinrade
Centre
8/8/2015
Maggie Sawczak
Provincial
8/8/2015
Maggie Sawczak
Centre
8/8/2015
Karen Chang
Mary Beth
Husson
Provincial
7/11/2015
Centre
7/11/2015
Lisa Turriff
Centre
7/11/2015
Karen Chang
Centre
7/11/2015
Marie
Kirchmeyer
Provincial
8/8/2015
Arlene Mete
Centre
8/8/2015
12-040
Lakeridge Health
Edeliza Mendoza
Centre
8/8/2015
The Ottawa Hospital
Amy Henderson
Centre
8/8/2015
Merck Canada Inc.
13-020
Merck Canada Inc.
Clovis Oncology,
Inc.
Clovis Oncology,
Inc.
Clovis Oncology,
Inc.
Clovis Oncology,
Inc.
NCIC Clinical
Trials Group
(NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
13-020
Hirte, Holger
(Hal) W.
Leighl, Natasha
B.
Leighl, Natasha
B.
13-042
Oza, Amit M.
13-042
13-042
Welch, Stephen
Weberpals,
Johanne
13-042
Oza, Amit M.
The Ottawa Hospital
UHN-Princess Margaret Cancer
Centre
13-044
Crump, Michael
Cheung ,
Matthew
UHN-Princess Margaret
Cancer Centre
Sunnybrook Health Sciences
Centre
12-041
13-044
Page 14 of 17
OCREB
#
REC
13-044
Kathie Zeman
13-045
Kathie
Zeman
13-045
Kathie Zeman
13-045
Kathie Zeman
13-045
Kathie Zeman
13-045
Kathie Zeman
13-045
Kathie Zeman
13-045
Kathie Zeman
13-045
Kathie Zeman
13-046
Aurora de
Borja
13-046
Aurora de
Borja
13-047
Aurora de
Borja
Kathie
Zeman
13-047
13-046
Sponsor
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical
Trials Group
(NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
Princess Margaret
Hospital
Consortium
(PMHC)
Princess Margaret
Hospital
Consortium
(PMHC)
Princess Margaret
Hospital
Consortium
(PMHC)
PI
Centre
Centre
Contact
13-044
Crump, Michael
UHN-Princess Margaret Cancer
Centre
13-045
Wong, Rebecca
K.S
UHN-Princess Margaret
Cancer Centre
13-045
Mahmud, Aamer
13-045
Kamra, Juhu
13-045
Berry, Scott
Wong, Rebecca
K.S
Gilbert ,
Sebastien
Protocol #
13-045
13-045
13-045
Expiry
Date
Marie Kirchmeyer
Centre
8/8/2015
Liesa Baumann
Provincial
8/8/2015
Kingston General Hospital
Royal Victoria Regional Health
Centre
Sunnybrook Health Sciences
Centre
UHN-Princess Margaret Cancer
Centre
Carrie Lindsay
Christine Di
Marco
Centre
8/8/2015
Centre
8/8/2015
Adam Lam
Centre
8/8/2015
Liesa Baumann
Centre
8/8/2015
The Ottawa Hospital
Lawson Health Research
Institute(London)
Amy Henderson
Centre
8/8/2015
Deb Lewis
Centre
8/8/2015
Grand River Hospital
Carol Ballantyne
Centre
8/8/2015
13-045
Frechette, Eric
Knight, Gregory
J.
13-046
Trudel,
Suzanne
UHN-Princess Margaret
Cancer Centre
Christine Tran
Provincial
8/8/2015
13-046
Hay, Annette
Elizabeth
Kingston General Hospital
Carrie Lindsay
Centre
8/8/2015
Christine Tran
Centre
8/8/2015
Bambie Sherwin
Provincial
8/8/2015
Bambie Sherwin
Centre
8/8/2015
Carolyn Lim
Centre
8/8/2015
Hamilton Health Sciences
Yvonne Kinrade
Centre
8/8/2015
Hamilton Health Sciences
Yvonne Kinrade
Provincial
8/8/2015
13-046
Merck Canada Inc.
13-047
Kathie Zeman
Merck Canada Inc.
13-047
13-047
Kathie Zeman
Merck Canada Inc.
13-047
13-047
Kathie Zeman
13-047
13-048
Kathie
Zeman
Merck Canada Inc.
Millennium
Pharmaceuticals
Inc.
Teleconference 2014-Jan-03
Application
Type
13-048
Trudel, Suzanne
Butler, Marcus
O
Butler, Marcus
O
Petrella, Teresa
Marie
McWhirter,
Elaine
Kouroukis,
Chrisostomos
(Tom)
UHN-Princess Margaret Cancer
Centre
UHN-Princess Margaret
Cancer Centre
UHN-Princess Margaret Cancer
Centre
Sunnybrook Health Sciences
Centre
Page 15 of 17
OCREB
#
REC
13-048
Kathie Zeman
13-048
14-014
Kathie Zeman
Kathie
Zeman
14-014
Sponsor
Millennium
Pharmaceuticals
Inc.
Millennium
Pharmaceuticals
Inc.
Protocol #
Centre
Centre
Contact
Application
Type
Expiry
Date
Sunnybrook Health Sciences
Centre
Arlene Mete
Centre
8/8/2015
Hamilton Health Sciences
Yvonne Kinrade
Centre
8/8/2015
13-048
Hsiao , Janey
Kouroukis,
Chrisostomos
(Tom)
Pfizer Canada Inc
14-014
Asmis, Tim
The Ottawa Hospital
Amy Henderson
Provincial
7/11/2015
Kathie Zeman
Pfizer Canada Inc
14-014
Asmis, Tim
7/11/2015
Kathie Zeman
Pfizer Canada Inc
14-014
Centre
7/11/2015
14-014
Kathie Zeman
Pfizer Canada Inc
14-014
Silvi Kuld
Centre
7/11/2015
14-014
Kathie Zeman
14-014
Adam Lam
Centre
7/11/2015
14-027
Cindy Sandel
Provincial
7/11/2015
Cindy Sandel
The Ottawa Hospital
UHN-Princess Margaret Cancer
Centre
Amy Henderson
14-027
Fatima Alas
Centre
7/11/2015
14-027
Cindy Sandel
14-027
The Ottawa Hospital
Amy Henderson
Centre
7/11/2015
14-028
Kathie
Zeman
14-028
Leighl, Natasha
B.
UHN-Princess Margaret
Cancer Centre
Maggie Sawczak
Provincial
7/11/2015
14-028
Kathie Zeman
Pfizer Canada Inc
AstraZeneca
Canada Inc.
AstraZeneca
Canada Inc.
AstraZeneca
Canada Inc.
Hoffmann-La
Roche Limited
(Canada)
Hoffmann-La
Roche Limited
(Canada)
Welch, Stephen
Chen, Eric
(Xueyu)
Ko, Yoo-Joung
(Yooj)
Wheatley-Price,
Paul
Shepherd,
Frances A.
Wheatley-Price,
Paul
Amy Henderson
Mary Beth
Husson
Centre
14-014
The Ottawa Hospital
Lawson Health Research
Institute(London)
UHN-Princess Margaret Cancer
Centre
Sunnybrook Health Sciences
Centre
UHN-Princess Margaret Cancer
Centre
Maggie Sawczak
Centre
7/11/2015
Eli Lilly Canada
14-029
St. Michael's Hospital
Jessica Petrucci
Provincial
7/11/2015
Eli Lilly Canada
14-029
Humber River Hospital
Julia Goldman
Centre
7/11/2015
Eli Lilly Canada
14-029
Jessica Petrucci
Mary Beth
Husson
7/11/2015
14-029
St. Michael's Hospital
Lawson Health Research
Institute(London)
Centre
Eli Lilly Canada
Hoffmann-La
Roche Limited
(Canada)
Hoffmann-La
Roche Limited
(Canada)
Leighl, Natasha
B.
BrezdenMasley,
Christine
Wilson ,
Jonathan
Brezden-Masley,
Christine
Dingle, Brian
Henry
Centre
7/11/2015
14-032
Verma, Sunil
Sunnybrook Health Sciences
Centre
Jeffrey Pham
Provincial
8/8/2015
14-032
Verma, Sunil
Sunnybrook Health Sciences
Centre
Jeffrey Pham
Centre
8/8/2015
14-029
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
Aurora de
Borja
14-032
Aurora de
Borja
14-032
Aurora de
Borja
14-029
14-029
14-029
Teleconference 2014-Jan-03
13-048
PI
14-027
14-027
14-028
Page 16 of 17
OCREB
#
REC
14-032
Aurora de
Borja
14-033
Cindy Sandel
14-033
Cindy Sandel
14-033
Cindy Sandel
14-034
Kathie
Zeman
14-034
Kathie Zeman
14-034
Kathie Zeman
14-034
Kathie Zeman
Teleconference 2014-Jan-03
Sponsor
Hoffmann-La
Roche Limited
(Canada)
Celldex
Therapeutics, Inc
Celldex
Therapeutics, Inc
Celldex
Therapeutics, Inc
NCIC Clinical
Trials Group
(NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
NCIC Clinical Trials
Group (NCIC CTG)
Protocol #
PI
14-032
Brezden-Masley,
Christine
14-033
Haq, Rashida
14-033
14-033
Application
Type
Expiry
Date
Aziz Jiwajee
Centre
8/8/2015
Jessica Petrucci
Provincial
8/8/2015
Verma, Sunil
St. Michael's Hospital
Sunnybrook Health Sciences
Centre
Jeffrey Pham
Centre
8/8/2015
Haq, Rashida
St. Michael's Hospital
Jessica Petrucci
Centre
8/8/2015
The Ottawa Hospital
UHN-Princess Margaret Cancer
Centre
Amy Henderson
Provincial
8/8/2015
Kendra Ross
Centre
8/8/2015
Hamilton Health Sciences
Yvonne Kinrade
Centre
8/8/2015
The Ottawa Hospital
Amy Henderson
Centre
8/8/2015
14-034
14-034
Jonker, Derek J.
14-034
Centre
Contact
St. Michael's Hospital
Jonker, Derek
J.
Razak , Albiruni
Ryan Abdul
Hotte, Sébastien
J.
14-034
Centre
Page 17 of 17